Top Wealth Group Holding Limited (NASDAQ: TWG) said it completed a US$80,000,000 private investment in public equity (PIPE) on July 22, 2026, issuing and selling 40,000,000 Class A ordinary shares at US$2.0 per share to nine non-U.S. investors. The company said the deal has closed and its total outstanding Class A ordinary shares increased to 59,579,883. The shares were issued in an unregistered private placement and are subject to transfer restrictions for six (6) months under Regulation S.

Samsung Biologics (KRX: 207940.KS) reported record second-quarter 2026 revenue of KRW 1,321 billion and operating profit of KRW 586 billion, and said cumulative contract value for the first half reached USD 21.6 billion. The company said Plant 5’s Process Performance Qualification (PPQ) work accelerated, while its all-cash public tender offer for PolyPeptide Group is expected to be completed toward the end of 2026. Samsung Biologics reiterated it remains on track to achieve the upper end of its previously announced 2026 guidance. The company said the results reflect sustained strength in its CDMO business and execution of global expansion plans.

AtlasClear Holdings (NYSE American: ATCH) has signed a non-binding letter of intent to acquire a profitable, internationally licensed institutional digital-asset business, and it has revised the terms of its planned acquisition of Dawson James. The amended terms are expected to allow an initial closing of 24.9% equity in about 30 days, with full ownership subject to regulatory and shareholder approvals. The company said the two transactions together are expected to add $35.4 million in 2025 revenue and $6.7 million in combined EBITDA, and based on unaudited revenue through June 2026, the combined 2026 revenue run rate is over $56 million.

A breakdown in the temporary U.S.-Iran ceasefire has again shut the Strait of Hormuz, while Yemen’s Houthi rebels have ended a four-year informal truce with Saudi Arabia and declared a blockade that could close the Bab El-Mandab Strait. Russia has also suspended diesel exports, which account for some 12% of the global market. The combined supply disruptions pushed diesel prices up P10–P12 per liter in a week, and oil is likely to stay above $80 per barrel for the next two or three quarters. The shock is expected to intensify pressure on global inflation and weigh on GDP.

Columbia Financial (CLBK) said it completed its second-step conversion and a $1.7 billion stock offering on July 20, 2026, and simultaneously closed its $580 million acquisition of Northfield Bancorp. After the transactions, the company reported total assets of $18.0 billion, deposits of $12.5 billion and loans of $11.9 billion, with more than 100 branches across New Jersey and in Staten Island and Brooklyn, New York. Columbia Financial shares are set to begin trading on Nasdaq on July 21 under the ticker CLBK.

Telix reported FY 2026 Q2 revenue of US$247 million, up 7% quarter over quarter and 21% year over year, and raised its full-year revenue outlook to more than US$1 billion. The company said the U.S. FDA confirmed its ProstACT Global Phase 3 study can move into Part 2 in the U.S., and set a PDUFA goal date of September 11, 2026 for Pixclara®. Telix also announced a strategic collaboration with Regeneron that includes an initial nonrefundable payment of US$40 million.

Quantum BioPharma said it plans to repay CAD$123,487.43 owed to third-party creditors and company insiders by issuing Class B common shares. The deemed issue price will be set at the lower of the prior trading day’s closing price on the CSE and CAD$4.26. The debt settlement involves no cash outlay and is described as a routine equity-financing action. The only asset referenced is the company’s own stock, QNTM, with no other traditional financial assets involved.

Monarch Casino & Resort (MCRI) reported second-quarter 2026 net revenue of $143 million, up 4.2% year over year, and adjusted EBITDA of $53 million, up 3.3%. Diluted EPS rose to $1.78, an increase of 23.6%, while cash and cash equivalents climbed to $138 million with no borrowings on its credit facility. The company maintained a $0.30 quarterly cash dividend and highlighted disciplined capital allocation and operating efficiency improvements across its Reno and Black Hawk properties.

Samsung Biologics (KRX: 207940.KS) said it will launch an all-cash public tender offer to acquire 100% of PolyPeptide Group AG (SIX: PPGN) at CHF 44.31 per share, implying an equity value of about CHF 1.46 billion. The offer price represents a 40% premium to PolyPeptide’s undisturbed share price of CHF 31.65. PolyPeptide’s board unanimously recommends shareholders accept the offer, and the company’s largest shareholder has agreed to tender its roughly 55.65% stake. The transaction is expected to complete toward the end of 2026, subject to customary conditions including a minimum acceptance threshold of 66⅔% and regulatory approvals.